Teladoc's Outlook Clouds As JPMorgan Points To Uncertainty In Behavioral Health, Margin Pressure
1. JPMorgan maintains Neutral rating on TDOC, lowering price target to $9. 2. Teladoc reported Q1 revenue of $629.4 million, missing earnings estimates. 3. The company anticipates a loss of $0.90-$1.40 per share for 2025. 4. Current challenges in DTC behavioral health create market uncertainty for Teladoc. 5. Despite challenges, growth potential remains with virtual care adoption expected.